Vitamin E for nonalcoholic steatohepatitis: Ready for prime time?
Jean‐François F. Dufour – 23 July 2010
CXC receptor‐2 knockout genotype increases X‐linked inhibitor of apoptosis protein and protects mice from acetaminophen hepatotoxicity
Bin Hu, Lisa M. Colletti – 23 July 2010 – Although acetaminophen is a commonly used analgesic, it can be highly hepatotoxic. This study seeks to further investigate the mechanisms involved in acetaminophen‐induced hepatotoxicity and the role of chemokine (C‐X‐C motif) receptor 2 (CXCR2) receptor/ligand interactions in the liver's response to and recovery from acetaminophen toxicity. The CXC chemokines and their receptor, CXCR2, are important inflammatory mediators and are involved in the control of some types of cellular proliferation.
Molecular characterization of the vascular features of focal nodular hyperplasia and hepatocellular adenoma: A role for angiopoietin‐1
Annette S. H. Gouw, Wenjiao Zeng, Marijke Buiskool, Inge Platteel, Marius C. van den Heuvel, Sibrand Poppema, Koert P. de Jong, Grietje Molema – 23 July 2010 – Focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA) are two hepatic nodular lesions of different etiologies. FNH, a polyclonal lesion, is assumed to be a regenerative reaction following a vascular injury, whereas HCA is a monoclonal, benign neoplastic lesion.
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C
Peter Derek Christian Leutscher, Martin Lagging, Mads Rauning Buhl, Court Pedersen, Gunnar Norkrans, Nina Langeland, Kristine Mørch, Martti Färkkilä, Simon Hjerrild, Kristoffer Hellstrand, Per Bech, for the NORDynamIC Group – 23 July 2010 – The Major Depression Inventory (MDI) was used to estimate the value of routine medical interviews in diagnosing major depression among patients receiving peginterferon alfa‐2a and ribavirin therapy for chronic hepatitis C virus (HCV) infection (n = 325).
Hepatitis B in refugees, guessing the prevalence
Jose Daniel Debes – 23 July 2010
The curative efficiency of tenofovir for patients with chronic hepatitis B after failure of nucleoside/nucleotide analogues
En‐Qiang Chen, Hong Tang – 23 July 2010
Reply:
Subrat Kumar Acharya – 23 July 2010
Antituberculosis therapy drug‐induced liver injury and acute liver failure
Harshad Devarbhavi, Ross Dierkhising, Walter K. Kremers – 23 July 2010
Transcriptome sequencing, microarray, and proteomic analyses reveal cellular and metabolic impact of hepatitis C virus infection in vitro
Stephen D. Woodhouse, Ramamurthy Narayan, Sally Latham, Sheena Lee, Robin Antrobus, Bevin Gangadharan, Shujun Luo, Gary P. Schroth, Paul Klenerman, Nicole Zitzmann – 23 July 2010 – Hepatitis C virus (HCV) is a major cause of liver disease but the full impact of HCV infection on the hepatocyte is poorly understood. RNA sequencing (RNA‐Seq) is a novel method to analyze the full transcriptional activity of a cell or tissue, thus allowing new insight into the impact of HCV infection.
Carbonyl reductase 1 as a novel target of (−)‐epigallocatechin gallate against hepatocellular carcinoma
Weixue Huang, Liya Ding, Qiang Huang, Hairong Hu, Shan Liu, Xianmei Yang, Xiaohui Hu, Yongjun Dang, Suqin Shen, Jie Li, Xiaona Ji, Songmin Jiang, Jun O. Liu, Long Yu – 23 July 2010 – Human carbonyl reductase 1 (CBR1) converts the antitumor drug and anthracycline daunorubicin (DNR) into the alcohol metabolite daunorubicinol (DNROL) with significantly reduced antitumor activity and cardiotoxicity, and this limits the clinical use of DNR. Inhibition of CBR1 can thus increase the efficacy and decrease the toxicity of DNR.